Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Clinical trial NCT07067268 · RECRUITING

Trial details

NCT number: NCT07067268
Sponsor: Fudan University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Nasopharyngeal Cancinoma (NPC)

Start date: 2024-09-14
Primary completion: 2026-09-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.